The revenue for Fibrosis and anti-TNF is expected to reach an annual total of $140 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Fibrosis and anti-TNF Overview
Anti-TNF monoclonal antibody is under development for the treatment of Dupuytren’s contracture, Post operative cognitive dementia (POCD), non-alcoholic steatohepatitis (NASH) and frozen shoulder syndrome. The drug candidate is administered through subcutaneous and intraarticular route.. It targets the tumor necrosis factor alpha. The drug candidate was also under development for the treatment of periarticular disease . It is a repurposed drug of adalimumab.
180 Life Sciences Overview
180 Life Sciences is developing new treatments for one of the world’s biggest drivers of disease. The company is headquartered in the US.
The operating loss of the company was US$54.8 million in FY2022, compared to an operating loss of US$15.7 million in FY2021. The net loss of the company was US$38.7 million in FY2022, compared to a net loss of US$20.3 million in FY2021.
For a complete picture of Fibrosis and anti-TNF’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.